November 2016, Lausanne, Switzerland:  The jury of the Prix Strategis, a CHF 50,000 prize in Swiss entrepreneurship, has selected CellSpring as a semifinalist.  The company is one of 8 semifinalists picked from a pool of 61 startup companies in Switzerland.  To read the jury's announcement, click here. (French language)

September 2016, Zürich, Switzerland: Each year, the Swiss startup monitor launches the "Top 100 Startup Award."  From over 100,000 young companies, the 100 most innovative and promising Swiss startups are picked by top startup experts.  We are honored to be selected for the 2016 class!

September 2016, Zürich, Switzerland, and Stevenage, United Kingdom:  Plasticell, the biotechnology company using combinatorial technologies for stem cell research and optimization of cell and gene therapy manufacturing, has announced it is collaborating with CellSpring, an innovative company that has developed a high throughput 3D cell culture system, the 3D Bloom® Biopolymer Platform, which enables more informed “stop/go” decisions for preclinical candidates.


Plasticell and CellSpring are developing tissue models using 3D Bloom Biopolymer seeded with hMSCs that are subsequently differentiated to bone, cartilage and brown/white fat tissue using CombiCult-derived differentiation media. 3D cultures of cells resemble natural tissues more closely compared to conventional 2D cultures grown on flat dishes. In particular, 3D tissues have more accurate biological responses to drug treatment and are used in the pharmaceutical industry to identify promising lead compounds in all stages of drug discovery.

August 2016, Mannedorf, Switzerland: CellSpring is honored to have been featured in the recent publication of the Tecan Journal.  To read the full text of the article, "A 3D Revolution," click here.

May 2016, Zürich, Switzerland: CellSpring and Tecan, the global leader in liquid handling robotics, have announced a co-marketing agreement to automate the 3D Bloom Biopolymer Platform on the Freedom EVO workstation.  This successful collaboration enables scientists to take advantage of CellSpring's 3D cell culture technology in a high throughput setting.  Dr. Chris Millan, Chief Technology Officer at CellSpring, commented, "CellSpring is excited to partner with Tecan to bring automated, simple 3D cell culture solutions to customers.  The benefits of our 3D Bloom Platform - versatility and reliability - are now available at scale using the Tecan Freedom EVO."


February 2016, Geneva, Switzerland: Bilan Magazine, the foremost publication covering the Swiss economy, has named CellSpring as one of the top 50 most investable startups in Switzerland for 2016.  CellSpring CEO Kramer Schmidt commented on the award: “CellSpring has the potential to change the landscape of 3D cell culture and beyond, and we are grateful to Bilan for this recognition.  Our team will use it as inspiration as we continue to push the boundaries of the opportunity before us.”

CellSpring makes key hires, ramps up product development



January 2016, Zürich, Switzerland: CellSpring AG is pleased to announce the hiring of Dr. med. vet. Flurina Clement Frey and Dr. Miriam Zimmermann.


Dr. med. vet. Clement Frey holds a PhD from the University of Bern. She comes to CellSpring from the University of Zürich, where she worked as a study director in the Center for Applied Biotechnology and Molecular Medicine. She brings extensive experience in managing and executing research projects as well as implementation of GLP quality. Dr. Clement Frey serves as Laboratory Director at CellSpring.


Dr. Zimmermann earned a PhD from The Institute of Cancer Research (ICR) in the UK. She joins CellSpring as a Project Manager after a PostDoc in the lab of Prof. Dr. Wilhelm Krek at the ETH Zürich. Her background in tumor biology and 3D cell culture systems will accelerate the commercialization of CellSpring's 3D Bloom® Platform.


Kramer Schmidt, CEO and co-founder of CellSpring, remarked on the growing team. "We could not be more excited to bring Flurina and Miriam on board.  They embody the energy, ambition, and experience that we look for in adding great people to CellSpring.  These key hires will expedite our time to market and broaden our capacity to continue innovating."


December 2015, San Francisco & London: CellSpring is honored to have been selected as a semifinalist of Oxbridge Onestart, the world’s largest accelerator for startups seeking to dramatically improve human health.  As a semifinalist, CellSpring placed in the top 10% of the more than 750 companies that applied to the program.  The semifinalist cohort was picked by judges from SR One (corporate venture capital arm of GlaxoSmithKline), Johnson & Johnson Innovation, Takeda Ventures, Bristol-Myers Squibb, AstraZeneca, Teva Pharmaceuticals, Boehringer Ingleheim, and Amgen.   CellSpring will participate in the Onestart Bootcamp in London in February.  Onestart finalists will be announced in April.



CellSpring & ETH awarded major grant from Swiss Commission for Technology & Innovation

November 2015, Bern, Switzerland: The Swiss Commission for Technology & Innovation has awarded the ETH and CellSpring a significant grant to advance shared research goals.  The grant will enable project partners to make key investments in development of the 3D Bloom® Biopolymer Platform.  Commenting on the grant award, CellSpring CTO Dr. Chris Millan said, “We are grateful to the CTI Commission for their trust and to our project partners for their enthusiasm for this project.  We look forward to putting these resources to work in the lab as we advance 3D in vitro research.”

November 2015, Winterthur, Switzerland: CellSpring was named a winner of the Heuberger Winterthur Entrepreneur Prize final, taking home an equity free grant of CHF 150k.

CellSpring AG Formed in Kanton Zürich



September 2015, Zürich, Switzerland: The co-founders are pleased to announce the official formation of CellSpring AG in Kanton Zürich, Switzerland.  Commenting on the company’s incorporation, CTO Dr. Chris Millan said, “We are so happy that CellSpring will formally call Zürich home.  The support of ETH, collaborating companies, and advisors in this region has boosted CellSpring tremendously.   The life sciences ecosystem here provides the perfect foundation for our company’s launch.”

September 2015, Zürich, Switzerland: CellSpring was named a finalist for the Heuberger Winterthur Entrepreneur’s Prize.  As a finalist, the company is guaranteed to receive at least CHF 50,000 in additional grant funding.  The final round will take place later in the fall, and winning companies will receive CHF 150,000 in grant funding.

May 2015, Zürich, Switzerland:  A jury of entrepreneurs, investors, and scientists has selected CellSpring as a winner of the Venture Kick final, and a CHF 130,000 investment.  CellSpring CEO Kramer Schmidt said, "We're thrilled to continue our journey in partnership with Venture Kick.  This investment, as well as their continued guidance, is invaluable as we execute on our vision to bring greater predictive power to drug development."

March 2015, Zürich, Switzerland: CellSpring CTO Chris Millan was selected as a 2015 Venture Leader.  Chosen out of over 100 candidates by a panel of investors and high-tech entrepreneurs, Chris will travel to Boston and New York in June for a highly intensive business development trip in partnership with swissnex Boston.



Chris Millan named Pioneer Fellow, CellSpring awarded 150,000 CHF in equity free capital.

December 2014, Zürich, Switzerland: CellSpring Co-Founder Chris Millan was selected by a panel of scientific experts as an ETH Zürich Pioneer Fellow.  The award was given based on the scientific merit of the 3D Bloom technology and its potential in the marketplace.  In addition to the 150,000 CHF in funding, the Fellowship enables CellSpring to utilize world-class lab and office space for research and business development activities.

November 2014, Zürich, Switzerland: CellSpring was one of two companies selected by the Venture Kick jury to win 20,000 CHF in pre-seed capital.  The Stage II Kick will provide funding for the company to execute pilot projects and expand business development activities in both Europe and the United States.  CellSpring now moves on to Stage III of the competition and an opportunity to win a 100,000 CHF investment.

June 2014, Lausanne, Switzerland: CellSpring was one of four companies selected by a jury of successful entrepreneurs and investors to win 10,000 CHF in pre-seed capital.  The company will now move on to Stage II of the Venture Kick competition, with an opportunity to win an additional 20,000 CHF.



CellSpring named winner of Sohr Grant Entrepreneurship Award

January 2014, Nashville, Tennessee: CellSpring was named the winner of the annual Sohr Grant Entrepreneurship Award at the Vanderbilt Owen Graduate School of Management.  Supported by Owen alum Jim Sohr, the Founder and CEO of AIM Healthcare, the grant provides $25,000 in equity free funding for early stage company development.  The competition was judged over an eight-week process by a panel of successful entrepreneurs led by Jim Sohr.  CellSpring won the award based on the strength of its business case and management team.

January 2014, Zurich, Switzerland: CellSpring was named to the Top 10 of the >>venture>>2014 ideas competition.  The company was chosen for the 2,500 CHF award out of a pool of 239 teams.  Co-Founders Kramer Schmidt and Chris Millan are pictured at left with the CEO of Roche Holding AG, Dr. Severin Schwan.


©2016. CellSpring. All Rights Reserved.